Introduction
If you are weighing up non-surgical options for joint wear, one of the practical questions is whether an injected material can actually stay where it is placed. This article explains how the ChondroFiller injection achieves natural adhesion and stability within the joint — and what that means in practice for patients considering this pathway.
ChondroFiller is a Class III CE-marked Type I collagen hydrogel scaffold, acellular (cell-free) by design, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. As a non-surgical treatment, it is delivered by ultrasound-guided injection rather than in an operating theatre.
Composition and Properties
ChondroFiller is supplied as a dual-component, single-use syringe. When the two components are co-extruded through a mixing adapter, the neutral pH triggers collagen fibrillogenesis: the liquid fills the three-dimensional geometry of the cartilage defect and then gels in situ, typically completing within three to five minutes at body temperature. The result is a biocompatible scaffold at approximately 8 mg/ml collagen concentration.
Because the gel forms after it is placed, it conforms precisely to the contours of the worn or damaged area rather than arriving as a pre-formed shape. This in-situ formation is central to both its fit and its stability.
Why Stitches Are Not Necessary
The gelled scaffold is self-adherent: it forms stable bonds with endogenous fibrin present in the surrounding cartilage and subchondral bone. This intrinsic adhesiveness means the implant remains securely fixed within the defect without requiring sutures, external fibrin glue, or anchors.
Clinical experience and published studies report no significant complications related to displacement. The ChondroFiller scaffold is designed to be acellular, recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone marrow once in place. It gradually resorbs over an expected residence time of one to two years as new tissue forms.
It is collagen-based and has biological potential, but it is best understood as a supportive, joint-preserving scaffold rather than a guaranteed regenerative cure. Benefits vary between patients, and it does not reverse established arthritis.
The Injection and Afterwards
The clinician prepares the worn area under ultrasound guidance and places the gel accurately into the defect. Patient positioning is important during application: the affected limb is orientated so that the defect is horizontal, preventing the liquid collagen from draining before it sets. Because ChondroFiller is a non-surgical injection — no theatre, no incision, no general anaesthetic — recovery is usually straightforward. Most people return to normal daily activities promptly, easing back into higher-impact activity as advised.
Accurate placement by an experienced clinician is important to achieving the intended adhesion and scaffold formation. The quality of the procedure directly influences how well the material sets and integrates.
How ChondroFiller Differs From Liquid Cartilage Surgery
It is worth clarifying the relationship between the ChondroFiller injection and Liquid Cartilage, as patients sometimes encounter both terms. They are not the same thing. ChondroFiller is the CE-marked collagen scaffold device; the ChondroFiller injection is its non-surgical, outpatient delivery route — the subject of this article.
Liquid Cartilage is an entirely separate concept: it refers to the Lee Liquid Cartilage Protocol, a keyhole (arthroscopic) surgical technique developed by Professor Paul Y. F. Lee. That protocol delivers the ChondroFiller scaffold plus biological adjuncts such as platelet-rich fibrin or plasma and, where indicated, the patient's own mesenchymal stem cells (from bone-marrow concentrate or micro-fragmented fat). It involves theatre, anaesthetic, and a structured rehabilitation programme, and is used for larger or load-bearing cartilage defects. The adhesion principles described in this article relate specifically to the ChondroFiller injection pathway, not to the Liquid Cartilage surgical protocol.
Summary
ChondroFiller is a non-surgical injection that adheres naturally to the joint surface without stitches or anchors, remaining stable as the joint moves. Its in-situ gelation allows it to conform to the exact shape of the defect, and its intrinsic adhesiveness to surrounding fibrin provides secure fixation. It may offer meaningful support for suitable patients, but benefits vary and it is not a cure for arthritis.
At the London Cartilage Clinic, patients receive individual assessment to determine whether the ChondroFiller injection, the Liquid Cartilage surgical protocol, or another pathway is most appropriate for their joint and circumstances. To arrange a consultation, please contact the clinic directly.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- When the two components of ChondroFiller are mixed and applied to the cartilage defect, the liquid gels in situ within a few minutes, conforming precisely to the surface. The resulting hydrogel forms stable bonds with endogenous fibrin in the surrounding tissue, providing secure fixation without the need for sutures, anchors, or external fibrin glue.
- No. Published studies and clinical experience consistently report that the gelled scaffold remains in place during normal joint movement. The self-adherent properties of the collagen matrix and its bonds with surrounding fibrin keep it stable once it has set.
- No — they are different things. The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure. Liquid Cartilage is Professor Paul Lee's keyhole surgical protocol, which delivers the ChondroFiller scaffold alongside biological adjuncts and, where indicated, the patient's own stem cells, in a theatre setting. A specialist assessment determines which pathway, if either, is appropriate for a given patient.
- Once the gel has set, it acts as an acellular scaffold that recruits the patient's own progenitor cells from the synovium and subchondral bone marrow. Over time — typically one to two years — the collagen matrix is gradually resorbed as newly formed tissue integrates with the repair site. The process supports cartilage regeneration but does not guarantee a specific outcome.
- Because the procedure is non-surgical, recovery is usually straightforward. Aftercare guidance focuses on a graduated return to activity, with physiotherapy recommended where helpful to support joint loading and function. Patients are advised to ease back into higher-impact activities progressively, following the clinician's recommendations.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
